Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SARS-CoV-2-University Hospital, Tours
- Development stage
- Preclinical
- Lead developer
- CHRU Tours
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intranasal
01
Overview
SARS-CoV-2-University Hospital, Tours refers to an intranasal protein subunit vaccine candidate developed by the University of Tours and the University Hospital of Tours, specifically by the BioMAP joint research unit (INRAE/University of Tours). The vaccine is designed to elicit a robust mucosal immune response by targeting both the spike (S) and nucleocapsid (N) proteins of the SARS-CoV-2 virus. Unlike systemic injectable vaccines, this candidate is administered via the nasal route to induce local secretory IgA antibodies and resident memory T-cells in the respiratory tract, which may provide a superior barrier against viral infection and transmission. The development of this vaccine is supported by the MUCOVID clinical study (NCT05934123), which aims to qualify the analytical methods required to measure mucosal immunity in human subjects.
- Other names
- MusiVacTours nasal vaccineINRAE-University of Tours nasal vaccine
02
Targets
N (Nucleocapsid protein)SARS-CoV-2 spike
Beyond the preview
Go deeper on SARS-CoV-2-University Hospital, Tours.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SARS-CoV-2-University Hospital, Tours.